Summary & Overview
HCPCS C9090: Injection, Plasminogen, Human-TVMH, 1 mg
HCPCS Level II code C9090 denotes a 1 mg vial of plasminogen, human-tvmh, for injection. As a biologic parenteral therapy, this code is used to bill for administered doses of a human-derived plasminogen product in clinical settings where injectable specialty therapies are delivered. Nationally, accurate use of this HCPCS Level II code supports appropriate billing for high-cost biologic products, inventory tracking, and payer coverage determinations.
Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context and typical sites of service, summaries of payer coverage patterns and coding considerations, and benchmarks related to billing and utilization where available. The publication also outlines common modifier usage and administrative considerations for specialty injectable biologics and highlights relevant policy updates affecting HCPCS Level II coding for biologic products.
The report is designed for revenue cycle professionals, clinicians involved in specialty drug administration, and policy analysts seeking a national perspective on coding, payer coverage, and the operational implications of billing for injectable plasminogen products.
Billing Code Overview
HCPCS Level II code C9090 represents Injection, plasminogen, human-tvmh, 1 mg. This code describes a single-milligram unit of a therapeutic plasminogen product derived from human sources intended for injection.
-
Service type: Parenteral biologic therapy
-
Typical site of service: Hospital outpatient departments, ambulatory infusion centers, physician offices, or specialty clinics where injectable biologic therapies are administered
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 3-year-old child with congenital plasminogen deficiency presents with progressive ligneous conjunctivitis causing recurrent membrane formation on the palpebral conjunctiva, resulting in persistent ocular irritation and visual axis compromise. The ophthalmology team prepares to administer an ophthalmic topical or subconjunctival biologic formulation of plasminogen derived from human source. The clinical workflow includes informed consent review, baseline ocular examination (visual acuity or age-appropriate assessment, slit-lamp exam), verification of diagnosis and prior therapies, allergy and medication reconciliation, and preparation of the reconstituted C9090 product (dosage calculated in milligrams). On the day of service the patient is taken to a procedure room or minor operating room depending on sedation needs. Local anesthesia or monitored sedation may be provided; topical or subconjunctival injection of C9090 is performed by an ophthalmologist or trained specialist. Post-procedure monitoring for infusion/injection reactions, ocular pressure checks, and instruction for follow-up dosing or ophthalmic care is documented. Billing uses the HCPCS Level II code C9090 for each 1 mg unit administered; appropriate CPT codes for the injection or procedural setting are appended as clinically applicable, and modifiers are applied to reflect unusual circumstances (for example, professional component, discontinued procedure, or assistant surgeon) per payer policy.
Coding Specifications
| Modifier | Description | When to Use |
|---|